Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Tumor-binding antibodies induce potent dendritic cell-mediated tumor immunity.

Carmi Y, Prestwood T, Engleman EG.

Oncoimmunology. 2018 May 7;8(10):e1078063. doi: 10.1080/2162402X.2015.1078063. eCollection 2019.

2.

A distinct subset of FcγRI-expressing Th1 cells exert antibody-mediated cytotoxic activity.

Rasoulouniriana D, Santana-Magal N, Gutwillig A, Farhat-Younis L, Wine Y, Saperia C, Tal L, Gutman H, Tsivian A, Brenner R, Bandora EA, Reticker-Flynn NE, Rider P, Carmi Y.

J Clin Invest. 2019 Oct 1;129(10):4151-4164. doi: 10.1172/JCI127590.

3.

Mechanism and Prevention of Titanium Particle-Induced Inflammation and Osteolysis.

Eger M, Hiram-Bab S, Liron T, Sterer N, Carmi Y, Kohavi D, Gabet Y.

Front Immunol. 2018 Dec 18;9:2963. doi: 10.3389/fimmu.2018.02963. eCollection 2018.

4.

Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation.

Kaplanov I, Carmi Y, Kornetsky R, Shemesh A, Shurin GV, Shurin MR, Dinarello CA, Voronov E, Apte RN.

Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1361-1369. doi: 10.1073/pnas.1812266115. Epub 2018 Dec 13.

5.

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes.

Santana-Magal N, Rasoulouniriana D, Saperia C, Gutwillig A, Rider P, Engleman EG, Carmi Y.

J Vis Exp. 2018 May 31;(135). doi: 10.3791/57188.

PMID:
29912184
6.

A distinct subset of plasmacytoid dendritic cells induces activation and differentiation of B and T lymphocytes.

Zhang H, Gregorio JD, Iwahori T, Zhang X, Choi O, Tolentino LL, Prestwood T, Carmi Y, Engleman EG.

Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):1988-1993. doi: 10.1073/pnas.1610630114. Epub 2017 Feb 6.

7.

Systemic Immunity Is Required for Effective Cancer Immunotherapy.

Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, Gherardini PF, Prestwood TR, Chabon J, Bendall SC, Fong L, Nolan GP, Engleman EG.

Cell. 2017 Jan 26;168(3):487-502.e15. doi: 10.1016/j.cell.2016.12.022. Epub 2017 Jan 19.

8.

Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations.

Rider P, Carmi Y, Cohen I.

Int J Cell Biol. 2016;2016:9259646. doi: 10.1155/2016/9259646. Epub 2016 Dec 19. Review.

9.

Akt and SHP-1 are DC-intrinsic checkpoints for tumor immunity.

Carmi Y, Prestwood TR, Spitzer MH, Linde IL, Chabon J, Reticker-Flynn NE, Bhattacharya N, Zhang H, Zhang X, Basto PA, Burt BM, Alonso MN, Engleman EG.

JCI Insight. 2016 Nov 3;1(18):e89020. doi: 10.1172/jci.insight.89020.

10.

Normalizing Microbiota-Induced Retinoic Acid Deficiency Stimulates Protective CD8(+) T Cell-Mediated Immunity in Colorectal Cancer.

Bhattacharya N, Yuan R, Prestwood TR, Penny HL, DiMaio MA, Reticker-Flynn NE, Krois CR, Kenkel JA, Pham TD, Carmi Y, Tolentino L, Choi O, Hulett R, Wang J, Winer DA, Napoli JL, Engleman EG.

Immunity. 2016 Sep 20;45(3):641-655. doi: 10.1016/j.immuni.2016.08.008. Epub 2016 Aug 30.

11.

Tumor-binding antibodies and tumor immunity.

Carmi Y, Engleman EG.

Oncotarget. 2015 Nov 3;6(34):35129-30. No abstract available.

12.

IMMUNOLOGY. An interactive reference framework for modeling a dynamic immune system.

Spitzer MH, Gherardini PF, Fragiadakis GK, Bhattacharya N, Yuan RT, Hotson AN, Finck R, Carmi Y, Zunder ER, Fantl WJ, Bendall SC, Engleman EG, Nolan GP.

Science. 2015 Jul 10;349(6244):1259425. doi: 10.1126/science.1259425.

13.

IL-1 Receptor Antagonist Chimeric Protein: Context-Specific and Inflammation-Restricted Activation.

Rider P, Carmi Y, Yossef R, Guttman O, Eini H, Azam T, Dinarello CA, Lewis EC.

J Immunol. 2015 Aug 15;195(4):1705-12. doi: 10.4049/jimmunol.1501168. Epub 2015 Jul 8.

14.

Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity.

Carmi Y, Spitzer MH, Linde IL, Burt BM, Prestwood TR, Perlman N, Davidson MG, Kenkel JA, Segal E, Pusapati GV, Bhattacharya N, Engleman EG.

Nature. 2015 May 7;521(7550):99-104. doi: 10.1038/nature14424. Epub 2015 Apr 29.

15.

Detection of intestinal cancer by local, topical application of a quenched fluorescence probe for cysteine cathepsins.

Segal E, Prestwood TR, van der Linden WA, Carmi Y, Bhattacharya N, Withana N, Verdoes M, Habtezion A, Engleman EG, Bogyo M.

Chem Biol. 2015 Jan 22;22(1):148-58. doi: 10.1016/j.chembiol.2014.11.008. Epub 2015 Jan 8.

16.

The role IL-1 in tumor-mediated angiogenesis.

Voronov E, Carmi Y, Apte RN.

Front Physiol. 2014 Mar 28;5:114. doi: 10.3389/fphys.2014.00114. eCollection 2014. Review.

17.

Interleukin-1α.

Rider P, Carmi Y, Voronov E, Apte RN.

Semin Immunol. 2013 Dec 15;25(6):430-8. doi: 10.1016/j.smim.2013.10.005. Epub 2013 Nov 1. Review.

PMID:
24183701
18.

Unique Versus Redundant Functions of IL-1α and IL-1β in the Tumor Microenvironment.

Voronov E, Dotan S, Krelin Y, Song X, Elkabets M, Carmi Y, Rider P, Idan Cohen, Romzova M, Kaplanov I, Apte RN.

Front Immunol. 2013 Jul 8;4:177. doi: 10.3389/fimmu.2013.00177. eCollection 2013.

19.

The role of IL-1β in the early tumor cell-induced angiogenic response.

Carmi Y, Dotan S, Rider P, Kaplanov I, White MR, Baron R, Abutbul S, Huszar M, Dinarello CA, Apte RN, Voronov E.

J Immunol. 2013 Apr 1;190(7):3500-9. doi: 10.4049/jimmunol.1202769. Epub 2013 Mar 8.

20.

Interleukin-1β regulates fat-liver crosstalk in obesity by auto-paracrine modulation of adipose tissue inflammation and expandability.

Nov O, Shapiro H, Ovadia H, Tarnovscki T, Dvir I, Shemesh E, Kovsan J, Shelef I, Carmi Y, Voronov E, Apte RN, Lewis E, Haim Y, Konrad D, Bashan N, Rudich A.

PLoS One. 2013;8(1):e53626. doi: 10.1371/journal.pone.0053626. Epub 2013 Jan 16.

21.

Sef is an inhibitor of proinflammatory cytokine signaling, acting by cytoplasmic sequestration of NF-κB.

Fuchs Y, Brunwasser M, Haif S, Haddad J, Shneyer B, Goldshmidt-Tran O, Korsensky L, Abed M, Zisman-Rozen S, Koren L, Carmi Y, Apte R, Yang RB, Orian A, Bejar J, Ron D.

Dev Cell. 2012 Sep 11;23(3):611-23. doi: 10.1016/j.devcel.2012.07.013.

22.

IL-1α and IL-1β recruit different myeloid cells and promote different stages of sterile inflammation.

Rider P, Carmi Y, Guttman O, Braiman A, Cohen I, Voronov E, White MR, Dinarello CA, Apte RN.

J Immunol. 2011 Nov 1;187(9):4835-43. doi: 10.4049/jimmunol.1102048. Epub 2011 Sep 19.

23.

Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis.

Carmi Y, Rinott G, Dotan S, Elkabets M, Rider P, Voronov E, Apte RN.

J Immunol. 2011 Mar 15;186(6):3462-71. doi: 10.4049/jimmunol.1002901. Epub 2011 Feb 7.

24.

p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner.

Addadi Y, Moskovits N, Granot D, Lozano G, Carmi Y, Apte RN, Neeman M, Oren M.

Cancer Res. 2010 Dec 1;70(23):9650-8. doi: 10.1158/0008-5472.CAN-10-1146. Epub 2010 Oct 15.

25.

Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation.

Cohen I, Rider P, Carmi Y, Braiman A, Dotan S, White MR, Voronov E, Martin MU, Dinarello CA, Apte RN.

Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2574-9. doi: 10.1073/pnas.0915018107. Epub 2010 Jan 25.

26.

The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis.

Carmi Y, Voronov E, Dotan S, Lahat N, Rahat MA, Fogel M, Huszar M, White MR, Dinarello CA, Apte RN.

J Immunol. 2009 Oct 1;183(7):4705-14. doi: 10.4049/jimmunol.0901511. Epub 2009 Sep 14.

27.

Role of IL-1-mediated inflammation in tumor angiogenesis.

Voronov E, Carmi Y, Apte RN.

Adv Exp Med Biol. 2007;601:265-70. Review.

PMID:
17713014
28.

The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions.

Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E.

Cancer Metastasis Rev. 2006 Sep;25(3):387-408. Review.

PMID:
17043764
29.

Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions.

Apte RN, Krelin Y, Song X, Dotan S, Recih E, Elkabets M, Carmi Y, Dvorkin T, White RM, Gayvoronsky L, Segal S, Voronov E.

Eur J Cancer. 2006 Apr;42(6):751-9. Epub 2006 Mar 10. Review.

PMID:
16530403
30.

Induction of antitumor immunity by CTL epitopes genetically linked to membrane-anchored beta2-microglobulin.

Margalit A, Sheikhet HM, Carmi Y, Berko D, Tzehoval E, Eisenbach L, Gross G.

J Immunol. 2006 Jan 1;176(1):217-24.

31.

Membrane-anchored beta 2-microglobulin stabilizes a highly receptive state of MHC class I molecules.

Berko D, Carmi Y, Cafri G, Ben-Zaken S, Sheikhet HM, Tzehoval E, Eisenbach L, Margalit A, Gross G.

J Immunol. 2005 Feb 15;174(4):2116-23.

32.

Roughening transition in dilute 3He-4He mixture crystals.

Carmi Y, Polturak E, Lipson SG.

Phys Rev Lett. 1989 Mar 20;62(12):1364-1367. No abstract available.

PMID:
10039655
33.

Critical behavior of vicinal surfaces of 4He.

Carmi Y, Lipson SG, Polturak E.

Phys Rev B Condens Matter. 1987 Aug 1;36(4):1894-1898. No abstract available.

PMID:
9943033
34.

Continuous and first-order wetting transitions of hcp 4He crystals.

Carmi Y, Lipson SG, Polturak E.

Phys Rev Lett. 1985 May 6;54(18):2042-2044. No abstract available.

PMID:
10031208

Supplemental Content

Support Center